169 related articles for article (PubMed ID: 22277577)
1. Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of 131I-MIBG.
Ezziddin S; Sabet A; Ko YD; Xun S; Matthies A; Biersack HJ
Radiat Oncol; 2012 Jan; 7():8. PubMed ID: 22277577
[TBL] [Abstract][Full Text] [Related]
2. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
[TBL] [Abstract][Full Text] [Related]
3. Functional imaging as an aid to decision-making in metastatic paraganglioma.
Bomanji JB; Hyder SW; Gaze MN; Gacinovic S; Costa DC; Coulter C; Ell PJ
Br J Radiol; 2001 Mar; 74(879):266-9. PubMed ID: 11338105
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effectiveness of iodine-131 MIBG metastases of a nonsecreting paraganglioma.
Baulieu JL; Guilloteau D; Baulieu F; Le Floch O; Chambon C; Pourcelot L; Besnard JC
J Nucl Med; 1988 Dec; 29(12):2008-13. PubMed ID: 3193214
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response.
Buscombe JR; Cwikla JB; Caplin ME; Hilson AJ
Nucl Med Commun; 2005 Nov; 26(11):969-76. PubMed ID: 16208174
[TBL] [Abstract][Full Text] [Related]
6. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
Gedik GK; Hoefnagel CA; Bais E; Olmos RA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
[TBL] [Abstract][Full Text] [Related]
7. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
8. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.
Loh KC; Fitzgerald PA; Matthay KK; Yeo PP; Price DC
J Endocrinol Invest; 1997 Dec; 20(11):648-58. PubMed ID: 9492103
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic effectiveness of 131I-MIBG on malignant pheochromocytoma--results of long-term follow-up].
Kusakabe K; Kanaya K; Kanaya S; Yazaki E; Nakano K; Matsumoto N; Kobayashi H; Maki M; Itou Y; Obara T
Kaku Igaku; 1994 Dec; 31(12):1495-502. PubMed ID: 7861648
[TBL] [Abstract][Full Text] [Related]
10. [131I]metaiodobenzylguanidine treatment of a malignant paraganglioma.
Baulieu JL; Guilloteau D; Calais G; Lefloch O; Besnard JC
J Nucl Biol Med (1991); 1991; 35(4):313-4. PubMed ID: 1823844
[TBL] [Abstract][Full Text] [Related]
11. Whole-body iodine-131 metaiodobenzylguanidine imaging for detection of bone metastases in patients with paraganglioma: comparison with bone scintigraphy.
Inoue T; Yoshinaga K; Morita K; Shiga T; Kanegae K; Hirata K; Okamoto S; Tamaki N
Ann Nucl Med; 2007 Jul; 21(5):307-10. PubMed ID: 17634850
[TBL] [Abstract][Full Text] [Related]
12. [131I]metaiodobenzylguanidine therapy in paraganglioma.
Castellani MR; Rottoli L; Maffioli L; Massimino M; Crippa F; Buraggi GL
J Nucl Biol Med (1991); 1991; 35(4):315-7. PubMed ID: 1823845
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S
J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368
[TBL] [Abstract][Full Text] [Related]
14. 131I-MIBG therapy of neural crest tumours (review).
Troncone L; Rufini V
Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
[TBL] [Abstract][Full Text] [Related]
15. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
16. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG.
Fishbein L; Bonner L; Torigian DA; Nathanson KL; Cohen DL; Pryma D; Cengel KA
Horm Metab Res; 2012 May; 44(5):405-10. PubMed ID: 22566196
[TBL] [Abstract][Full Text] [Related]
17. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
[TBL] [Abstract][Full Text] [Related]
18. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Castellani MR; Chiti A; Seregni E; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
[TBL] [Abstract][Full Text] [Related]
19. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.
Gao Z; Biersack HJ; Ezziddin S; Logvinski T; An R
J Cancer Res Clin Oncol; 2004 Nov; 130(11):649-56. PubMed ID: 15300425
[TBL] [Abstract][Full Text] [Related]
20. Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine.
Bomanji J; Britton KE; Ur E; Hawkins L; Grossman AB; Besser GM
Nucl Med Commun; 1993 Oct; 14(10):856-61. PubMed ID: 8233228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
